Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Evidence for the benefits of prophylaxis in the management of hemophilia A

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

COX-2 inhibitors and the thrombotic risk

Issue: 2006: 96/4 (Oct) pp. 391-543
Pages: 433-440

Evidence for the benefits of prophylaxis in the management of hemophilia A

W. Keith Hoots1,2, Diane J. Nugent3,4
1Department of Pediatrics and Internal Medicine, University of Texas Medical School, Houston, Texas, USA; 2Department of Pediatrics, University of Texas – M.D. Anderson Cancer Center, Houston, Texas, USA; 3Department of Hematology, Children’s Hospital


cost-benefit, factor VIII, prophylaxis, hemophilia, on-demand, arthropathy


The optimal treatment of hemophilia has been evolving since the advent of factor VIII concentrates, continues to vary geographically, and remains a source of debate.There now exists an extensive clinical literature that demonstrates clear benefits of prophylaxis for patients with hemophiliaA compared to on-demand treatment, including a reduction in the number of bleeding episodes, improved joint function, and greater patient well-being. However, the value of these benefits must be weighed against the heavier economic burden of increased factor use.This paper reviews the literature that compares the benefits of prophylaxis with that of on-demand treatment, compares varying prophylaxis dose and administration frequency protocols, and considers the long-term cost-benefit of prophylactic therapy.

You may also be interested in...

Deborah A. Lewis, Karen D. Moore, Thomas L. Ortel

Thromb Haemost 2001 85 2: 260-264

Actual treatment situation in a haemophilia centre

B. Siegmund (1), H. Richter (1), H. Pollmann (1)

Hämostaseologie 2010 30 Suppl. 1: S32-S34

The HemArthro-Project

T. Hilberg (1), D. Czepa (1)

Hämostaseologie 2009 29 Suppl. 1: 77-79